Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Up 117.6% in April

Lonza Group Ag (OTCMKTS:LZAGY) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 27,348 shares, a growth of 117.6% from the April 15th total of 12,566 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 119,668 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Several brokerages have recently issued reports on LZAGY. Royal Bank Of Canada upgraded Lonza Group from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, February 11th. Zacks Research upgraded Lonza Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Lonza Group Stock Down 2.0%

OTCMKTS LZAGY opened at $59.51 on Friday. Lonza Group has a 12 month low of $58.53 and a 12 month high of $73.85. The company’s 50 day simple moving average is $63.07 and its 200 day simple moving average is $66.30. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.